Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type B conjugate vaccine or as pentavalent vaccine

Pediatric Infectious Disease Journal

Volumn 16, Issue 8, 1997, Pages 787-794

  Bégué, Pierre ^a   Stagnara, Jean ^a   Vie Le Sage, François ^a   Bernard, Jean Claude ^b   Xerri, Bertrand ^c   Abitbol, Véronique ^c  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c SmithKline Beecham   (France)

Author keywords

Acellular; Booster; Pertussis; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; CHILD; DIPHTHERIA; HUMAN; IMMUNOREACTIVITY; INFECTION PREVENTION; NORMAL HUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; POLYSACCHARIDES, BACTERIAL;

EID: 0342327341     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199708000-00011     Document Type: Article

References (41)

1. Karsenty JY, Roure C, Vidal-Trecan G. La coqueluche en France. Bull Epidemiol Hebdomadaire 1990;19:81-3.
2. Bégué P, Grimprel E. La coqueluche en France après 25 ans de large couverture vaccinale. Med Mal Infect 1992; 22(Suppl):79.
3. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987;6:364-71.
4. Bégué P, Grimprel E, Roure C, Guiso N. La coqueluche en France: nécessité de mise en place d'une surveillance. Bull Epidemiol Hebdomadaire 1992;48:227-9.
5. Bégué P, Baron S, Grimprel E. Épidémiologie de la coqueluche en Europe en 1995. Med Mal Infect 1995;25(Suppl): 1263-7.
6. Baron S, Bégué P, Desenclos JC, et al. Évaluation épidémiologique, clinique et microbiologique de la coqueluche en France en 1993-1994. Bull Epidemiol Hebdomadaire 1995; 19:83-5.
7. Comité Technique des Vaccinations, Direction Générale de la Santé. Guide pratique des vaccinations. Comité Français d'Education pour la Santé, Paris, 1995:62-8.
8. Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N. Long term human serum antibody responses after immunization with whole cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996;3:93-7.
9. Binkin NJ, Salmaso S, Tozzi AE, Scuderi G, Greco S. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 1992;11:653-61.
10. Bégué P, Baron S, Grimprel E. Épidémiologie de la coqueluche en Europe en 1995. Méd Mal Infect 1995;25(Suppl): 1263-7.
11. Bass JW, Stevenson SR. The return of pertussis. Pediatr Infect Dis J 1987;6:141-4.
12. CDC. Resurgence of pertussis: United States 1993. MMWR 1993;42:952-60.
13. Lukenkampff M, Schwartzmann JS, Wilson J. Neurological complications of pertussis inoculation. Arch Dis Child 1974; 49:46-9.
14. Golden GS. Pertussis vaccine and injury to the brain. J Pediatr 1990;116:854-61.
15. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations of infants and children. Pediatrics 1981;68:650-60.
16. Griffiths AH. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine 1989;7:199-210.
17. Pizza M, Covacci A, Bartoloni A, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989;246: 497-500.
18. Burnette WN, Mar VL, Bartley TD, et al. The molecular engineering of pertussis toxoid. Dev Biol Stand 1991;73:75-8.
19. Englund JA, Glezen WP, Barreto J. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis 1992;166:1436-41.
20. Anderson EL, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis 1988;157:731-7.
21. Edwards KM, Meade BM, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-57.
22. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
23. Kimura M, Sakai HK. Developments in pertussis immunization in Japan. Lancet 1990;336:30-2.
24. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
25. Gustafsson L, Hallander HO, Olin P, Reigenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole cell pertussis vaccine. N Engl J Med 1996;334:349-55.
26. Pichichero ME, Christy C, Decker MD, et al. Defining the key parameters for comparing reactions among acellular and whole cell pertussis vaccines. Pediatric 1995;96(Part 2):588-92.
27. Melville-Smith ME, Seagroatt Va, Watkins JT. A comparison of enzyme-linked immunosorbent assay (Elisa) with the toxin neutralization test in mice as a method of the estimation of tetanus antitoxin in human sera. J Biol Stand 1983;11:137-44.
28. Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984;20:772-4.
29. Granstrom M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987;6:18-21.
30. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (Elisa). J Immunol Methods 1987;103:189-94.
31. Sato Y et al. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. In: Robbins JB, Hill JC, Sardoff JC, eds. Seminars in infectious diseases: bacterial vaccines. New York: Thieme-Stratton, 1982:380-5.
32. Albrecht P. Standardization of polio virus neutralizing antibody tests. Rev Infect Dis 1984;6(Suppl 2):5540-44.
33. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective levels of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
34. Robbins J. B., Parke J. C., Schneerson R., Whisnant J. K. Quantitative measurement of "natural" and immunization induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973;7:103-110.
35. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984;149:1034-5.
36. Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and PRN outer membrane protein as a booster in children. Eur J Pediatr 1993;152:478-83.
37. Bernstein HH, Rothstein EP, Penridge PA. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15-through 20-month-old infants. Pediatrics 1994:93:656-9.
38. Bernstein DI, Smith VE, Schiff GM, Rathfon HM, Boscia JM. Comparison of acellular pertussis vaccine with whole-cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr Infect Dis J 1993;12:131-5.
39. Blumberg D. A., Mink C. M., Cherry J. D., et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr 1991;119: 194-204.
40. Eskola J, Olander R, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348:1688-92.
41. Schmitt HJ. Immunogenicity and reactogenicity of 2 Hib tetanus conjugate vaccines administered by reconstituting with DTPa or given as separate injections [Abstract G63]. In: Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995.